John Valliant
Fondateur chez FUSN PHAR
Fortune : 7 M $ au 30/04/2024
Postes actifs de John Valliant
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| FUSN PHAR | Directeur/Membre du Conseil | 01/12/2014 | - |
| Directeur Général | 01/12/2014 | - | |
| Fondateur | 01/12/2014 | - | |
Centre For Probe Development & Commercialization
 Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | Directeur/Membre du Conseil | 01/03/2008 | - |
| Fondateur | 01/03/2008 | - | |
| Independent Dir/Board Member | 01/03/2008 | - | |
| McMaster University | Corporate Officer/Principal | 01/01/1999 | - |
Historique de carrière de John Valliant
Formation de John Valliant
| McMaster University | Doctorate Degree |
Statistiques
Internationale
| Canada | 4 |
Opérationnelle
| Director/Board Member | 2 |
| Founder | 2 |
| Chief Executive Officer | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| FUSN PHAR | Health Technology |
| Entreprise privées | 1 |
|---|---|
Centre For Probe Development & Commercialization
Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | Health Technology |
- Bourse
- Insiders
- John Valliant
- Expérience
